Phase 1b of the second trial is designed to investigate the activity and safety of the RP2D in two advanced breast cancer expansion cohorts: one cohort with HER2 positive patients, and one cohort with HER2-low patients (clinicaltrials.gov identifier: NCT03255070). Here, ERBB2 is linked to breast cancer.